Pages that link to "Item:Q3637001"
From MaRDI portal
The following pages link to Related Causal Frameworks for Surrogate Outcomes (Q3637001):
Displaying 35 items.
- External validity: from do-calculus to transportability across populations (Q252808) (← links)
- A causal framework for surrogate endpoints with semi-competing risks data (Q712513) (← links)
- Causal measures of the treatment effect captured by candidate surrogate endpoints (Q887978) (← links)
- Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption (Q2170431) (← links)
- Bayesian methods for multiple mediators: relating principal stratification and causal mediation in the analysis of power plant emission controls (Q2281243) (← links)
- The identification of direct and indirect effects in studies with an unmeasured intermediate variable (Q2791838) (← links)
- Statistical evaluation of surrogate endpoints with examples from cancer clinical trials (Q2792764) (← links)
- An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference (Q2827172) (← links)
- Design and estimation for evaluating principal surrogate markers in vaccine trials (Q2846433) (← links)
- Surrogate measures and consistent surrogates (Q2861938) (← links)
- Comparing biomarkers as principal surrogate endpoints (Q2893405) (← links)
- Evaluating correlation-based metric for surrogate marker qualification within a causal correlation framework (Q2912363) (← links)
- Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials (Q3076045) (← links)
- Augmented Designs to Assess Principal Strata Direct Effects (Q3107200) (← links)
- Estimation of Direct Effects for Survival Data by using the Aalen Additive Hazards Model (Q3107203) (← links)
- Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling (Q3119801) (← links)
- Bayesian inference for causal mediation effects using principal stratification with dichotomous mediators and outcomes (Q3305026) (← links)
- On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints (Q3465713) (← links)
- A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials (Q3576929) (← links)
- Bayesian Inference for the Causal Effect of Mediation (Q4911924) (← links)
- Partially Hidden Markov Model for Time-Varying Principal Stratification in HIV Prevention Trials (Q4916438) (← links)
- A Multiple Imputation Approach for the Evaluation of Surrogate Markers in the Principal Stratification Causal Inference Framework (Q4984852) (← links)
- Discussion on ``Surrogate measures and consistent surrogates'' (Q5891278) (← links)
- Discussion on ``Surrogate measures and consistent surrogates'' (Q5891279) (← links)
- Rejoinder on: ``Surrogate measures and consistent surrogates'' (Q5891280) (← links)
- Equivalence between direct and indirect effects with different sets of intermediate variables and covariates (Q5963507) (← links)
- Evaluation of longitudinal surrogate markers (Q6050955) (← links)
- Proportion of treatment effect mediated by surrogate endpoints (Q6067311) (← links)
- Robust Approach to Combining Multiple Markers to Improve Surrogacy (Q6079767) (← links)
- Testing for Heterogeneity in the Utility of a Surrogate Marker (Q6079768) (← links)
- Surrogacy validation for time-to-event outcomes with illness-death frailty models (Q6625395) (← links)
- Flexible evaluation of surrogate markers with Bayesian model averaging (Q6630321) (← links)
- An information-theoretic approach for the assessment of a continuous outcome as a surrogate for a binary true endpoint based on causal inference: application to vaccine evaluation (Q6630352) (← links)
- Simultaneous inference of treatment effect modification by intermediate response endpoint principal strata with application to vaccine trials (Q6636037) (← links)
- Generalizing the Intention-to-Treat Effect of an Active Control from Historical Placebo-Controlled Trials: A Case Study of the Efficacy of Daily Oral TDF/FTC in the HPTN 084 Study (Q6651352) (← links)
